[go: up one dir, main page]

NO20040214L - Kombinasjoner som innebefatter epotiloner og farmasoytiske anvendelser derav - Google Patents

Kombinasjoner som innebefatter epotiloner og farmasoytiske anvendelser derav

Info

Publication number
NO20040214L
NO20040214L NO20040214A NO20040214A NO20040214L NO 20040214 L NO20040214 L NO 20040214L NO 20040214 A NO20040214 A NO 20040214A NO 20040214 A NO20040214 A NO 20040214A NO 20040214 L NO20040214 L NO 20040214L
Authority
NO
Norway
Prior art keywords
epothilones
pharmaceutical applications
combinations involving
involving
combinations
Prior art date
Application number
NO20040214A
Other languages
English (en)
Inventor
John David Rothermel
Diane Greeley
Tianling Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040214L publication Critical patent/NO20040214L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20040214A 2001-07-19 2004-01-16 Kombinasjoner som innebefatter epotiloner og farmasoytiske anvendelser derav NO20040214L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30657101P 2001-07-19 2001-07-19
US30656001P 2001-07-19 2001-07-19
US30655901P 2001-07-19 2001-07-19
PCT/EP2002/008020 WO2003007924A2 (en) 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
NO20040214L true NO20040214L (no) 2004-03-18

Family

ID=27405180

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040214A NO20040214L (no) 2001-07-19 2004-01-16 Kombinasjoner som innebefatter epotiloner og farmasoytiske anvendelser derav

Country Status (19)

Country Link
US (3) US20040235796A1 (no)
EP (2) EP2210643A3 (no)
JP (2) JP2005501825A (no)
KR (2) KR20090040925A (no)
CN (2) CN101791308A (no)
AU (2) AU2002328921B2 (no)
BR (1) BR0211271A (no)
CA (1) CA2453108A1 (no)
CO (1) CO5560565A2 (no)
EC (2) ECSP084948A (no)
HU (1) HUP0401153A3 (no)
IL (2) IL159517A0 (no)
MX (1) MXPA04000567A (no)
NO (1) NO20040214L (no)
NZ (2) NZ550174A (no)
PL (1) PL365030A1 (no)
RU (1) RU2375058C2 (no)
TW (1) TWI315982B (no)
WO (1) WO2003007924A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR20040025904A (ko) 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
CN102274230B (zh) 2003-11-18 2015-07-01 诺华股份有限公司 Kit突变形式的抑制剂
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
PL1879585T3 (pl) 2005-05-02 2013-08-30 Novartis Ag Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EA035193B1 (ru) 2010-05-18 2020-05-14 Серулин Фарма Инк. Композиции и способы лечения аутоиммунных и других заболеваний
RU2478407C1 (ru) * 2011-09-05 2013-04-10 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Способ комбинированного лечения местно-распространенного рака желудка

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) * 1946-10-22 Method for obtaining hydantoins
US3475486A (en) * 1966-09-12 1969-10-28 Monsanto Co Process for preparing phosphonic acids
NL7304882A (no) 1972-04-10 1973-10-12
CH605550A5 (no) 1972-06-08 1978-09-29 Research Corp
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
AU5953894A (en) 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
PT833643E (pt) * 1995-06-06 2005-06-30 Merck & Co Inc Formulacoes de sal anidro de alendronato
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE59610712D1 (de) * 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1052974T3 (da) * 1998-02-05 2009-08-10 Novartis Ag Farmaceutisk sammensætning indeholdende epothilon
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ES2313883T3 (es) 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
JP2003519183A (ja) * 2000-01-04 2003-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
ES2241781T3 (es) 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.
KR20040025904A (ko) 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof

Also Published As

Publication number Publication date
US20040235796A1 (en) 2004-11-25
US20080119529A1 (en) 2008-05-22
IL159517A (en) 2012-04-30
RU2004105144A (ru) 2005-04-20
EP1412029A2 (en) 2004-04-28
CA2453108A1 (en) 2003-01-30
JP2010159271A (ja) 2010-07-22
BR0211271A (pt) 2004-08-03
HUP0401153A2 (hu) 2004-10-28
CO5560565A2 (es) 2005-09-30
US8008330B2 (en) 2011-08-30
KR20090040925A (ko) 2009-04-27
TWI315982B (en) 2009-10-21
AU2005246964B2 (en) 2008-04-24
WO2003007924A2 (en) 2003-01-30
US20090318390A1 (en) 2009-12-24
JP2005501825A (ja) 2005-01-20
WO2003007924A3 (en) 2003-09-25
ECSP084948A (es) 2008-08-29
AU2002328921B2 (en) 2006-11-02
NZ530572A (en) 2006-11-30
KR20040030808A (ko) 2004-04-09
NZ550174A (en) 2008-04-30
PL365030A1 (en) 2004-12-27
CN101791308A (zh) 2010-08-04
EP2210643A2 (en) 2010-07-28
MXPA04000567A (es) 2004-04-20
EP2210643A3 (en) 2010-11-24
ECSP094948A (es) 2009-12-28
RU2375058C2 (ru) 2009-12-10
CN1283248C (zh) 2006-11-08
IL159517A0 (en) 2004-06-01
HUP0401153A3 (en) 2008-01-28
CN1533293A (zh) 2004-09-29
US7612052B2 (en) 2009-11-03
AU2005246964A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DK1373191T3 (da) Acylerede indanylaminer og deres anvendelse som lægemidler
EE200300416A (et) Ravimvorm
NO20033384D0 (no) Farmasöytisk formulering
NO20042084L (no) 6-hydroksyisoflavoner, derivater og legemidler som omfatter disse
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
FI20011478A0 (fi) Farmaseuttinen koostumus
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
DE50201711D1 (de) Mikroventil
NO20035315D0 (no) Farmasöytiske kombinasjoner
NO20035627D0 (no) Farmasöytisk formulering
DE50201549D1 (de) Rückflussverhinderer
NO20040214L (no) Kombinasjoner som innebefatter epotiloner og farmasoytiske anvendelser derav
FI20022128A0 (fi) Farmaseuttinen koostumus
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1363490T3 (da) Agrokemiske præparater
NO20042693L (no) Kateterpreparat og anvendelser derav
DE50200795D1 (de) Mikroventil
NO20033709D0 (no) Medisinske preparater omfattende Diklofenak og Ornoprostil
NO20034785D0 (no) Farmasöytiske kombinasjoner basert på pyridoindolon-derivater og anticancermidler
DE60219418T8 (de) Silanylphenole und -naphthole
NO20041236L (no) Farmasoytisk formulering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application